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 When should screening for diabetic retinopathy begin for children with type 1 diabetes? 
 
Treatment of diabetic retinopathy  
Visual impairment and blindness as a result of diabetic retinopathy (DR) is amongst the most feared 
complication of diabetes. However, the prevalence of sight threatening diabetic retinopathy (STDR) 
has been slowly decreasing [1-4]. Recently it has been reported that diabetes is no longer the 
leading cause of blindness in the working age population in the UK [5].  These observations may 
reflect the cumulative impact of better management of diabetes, the introduction of screening 
programmes aiming to identify STDR and more active and effective ophthalmologic management.  
Good glycaemic and blood pressure control are pivotal in the primary prevention of DR with some 
evidence of direct benefit from fibrates when used in those with dyslipidaemia [6, 7]. The 
introduction of intensive insulin therapy to optimise glycaemic control In children with type 1 
diabetes aged 13-17 years was seen to reduce the risk of developing DR by 53% [8]. The benefit of 
such intensive management in the adolescent years remained evident many years later (legacy 
effect) even when HbA1c values were similar for the intensively treated and control groups [9]. 
Currently treatment for STDR, which encompasses proliferative DR (PDR) and selected cases of 
severe non-proliferative DR (pre-proliferative DR, (PPDR) and maculopathy, is primarily by laser 
photocoagulation and more recently in conjunction with intra-vitreal injections of inhibitors of 
vascular endothelial growth factors (anti-VEGF). The relatively recent addition of anti-VEGF 
treatment has improved visual outcomes in those with PDR and clinically significant macular oedema 
(CSMO) [10].  If these measures are deemed inadequate then vitrectomy maybe required.  It is 
generally acknowledged that diabetic retinopathy remains asymptomatic until it reaches an 
advanced stage (STDR) and that the benefit from treatment with laser photocoagulation is best 
achieved the earlier the diagnosis and treatment is delivered.  This is the basis for the introduction of 
screening for DR which has also been shown to be cost-effective especially in comparison to the 
societal cost of blindness [11]. The detection of any DR will help to prompt the need for improving 
and maintaining good glycaemic control to prevent progression to STDR. In the context of this 
review glycaemic control is usually worse in adolescents compared with younger age children [12] 
 
Guidelines for diabetic retinopathy screening in children and young persons with diabetes 
DR screening programmes have been instituted in several countries over the last 20 years, aiming for  
the early detection and close monitoring of retinal changes related to diabetes in an attempt to 
prevent loss of vision or blindness as the primary goal and secondarily, to instigate interventions to 
prevent the progression of non-sight threatening DR. National structured and community based DR 
screening programmes for diabetic retinopathy have been operational in the UK since 2003. 
Currently screening is offered to all persons with diabetes from the age of 12 years, and carried out 
on an annual basis as recommended by the Royal College of Ophthalmologists [13].  However, the 
question remains unresolved as to when is the most appropriate age to begin screening for DR in 
persons with type 1 diabetes. Recommendations vary between programmes/countries either based 
on duration of diabetes or age of the children (Table 1).  The American Academy of ophthalmology 
currently recommends annual screening for all with a duration of diabetes of more than 5 years, 
whilst the American Academy of Paediatrics recommends an initial screening 3-5 years after 
diagnosis of diabetes if over age 9 and annually thereafter and the American Diabetes Association 
also recommends screening begins 3-5 years after diagnosis of diabetes and once the child is 10 
years old.  However in Europe, the International Society for Pediatric and Adolescent Diabetes 
(2011) recommends screening for DR from the age of 11 years after 2 years of diabetes and from the 
age of 9 years for those with diabetes of 5 years or more. The  Retinopathy working party 
recommends screening from the onset of puberty [14]. In Scandinavia, Finland  begin DR screening  
when patients enter puberty [15], and Sweden commence DR screening from the age of 10 years 
[16]. 
 
Prevalence of diabetic retinopathy in children 
The evidence indicates that the prevalence of diabetic retinopathy in children is low and is extremely 
rare prior to puberty [17, 18].  The prevalence of DR has been found in children and young persons 
with diabetes ranges between 10.5% and 57.6% depending on the inclusion age and duration of 
diabetes at the time of screening and adopted methods of screening for DR (Table 1) [18-31].   
The youngest age at which DR has been observed was 5 years [28] and the youngest age at which 
sight-threatening DR was reported was 15 years with the shortest duration of diabetes being 5 years 
[32] with only 5 cases of sight-threatening DR in children <18 years [28, 32]. However, in a recent 
study of 370 children with diabetes aged <18 years no cases of DR were found [25] prompting the 
suggestion that screening for DR be delayed to the age of 15 years or once duration of diabetes is 5 
years whichever comes later and also on the basis that few require treatment for sight-threatening 
DR at an earlier age. Some clinicians have also suggested that screening for DR at such a young age 
may theoretically  have a psychosocial impact creating stress and anxiety, which is an area that 
requires further examination.   
In our experience involving 1,770 children and young people with diabetes aged 12 to 18 years with 
type 1 diabetes undergoing screening for the first time in the Diabetic Retinopathy Screening Service 
for Wales (DRSSW) the prevalence of DR was 17.4%, consisting of 17.1% non-sight-threatening DR 
and 0.3% sight-threatening DR [33]. Of those with sight-threatening DR 1 person was found to have 
PPDR, 4 had maculopathy and none had PDR. The youngest with sight-threatening DR was aged 14 
years. Eleven point nine percent presented with non-sight-threatening DR aged 12-13 years.  
Adjusting for gender and duration of diabetes those aged 14-16 years and ≥17 years were 2.8 fold 
and 2.9 fold respectively more likely to develop DR compared to those aged ≤13 years.   Diagnosing 
non-sight threatening DR at this early stage allows appropriate enhancement of diabetes 
management in an attempt to near-normalise metabolic control to avoid any further deterioration 
of the DR [8].   
 
Recommendations 
It is imperative to assess the positive and negative impact of screening for DR on children and young 
persons with type 1 diabetes. In general, screening programmes have the potential to generate 
anxiety. Further investigation should be undertaken to fully evaluate the early introduction of 
screening in this population. Whilst it is recognised that few type 1 subjects require laser 
photocoagulation for STDR before mid-teens, the earlier detection of DR affords an opportunity to 
improve glycaemic control and the other putative risk factors including BP to prevent progression to 
STDR. However, what benefits accrue in clinical practice remains unclear. Further debate is now 
required to review in detail the available evidence, together with input from patients, 
parents/guardians, paediatric diabetologists and ophthalmologists to reach a consensus as to what 
age DR screening should commence in children and young persons with type 1 diabetes. Until such 
time delaying starting DR screening beyond the age of 12 years cannot be justified. 
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